Novel Glaucoma Diagnostics
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWills Eye
About this trial
The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases
Eligibility criteria
Qualifiers
Ability to provide informed consent and to understand the study procedures
Healthy volunteers
Age related macular degeneration (AMD), diabetic retinopathy, central serous chorioretinopathy, and/or glaucoma or glaucoma suspects
(AD Sub-Study ONLY): Subjects diagnosed with AD or MCI.
Disqualifiers
Any medical treatment (e.g., chronic corticosteroid, hydroxychloroquine, chloroquine, thioridazine, canthaxanthine) or conditions that affect VF (e.g., stroke) and retinal thickness other than glaucoma.
Strabismus, nystagmus, or any condition that prevents fixation.
Presence of any media opacities that hinders clinical view of the fundus, and any intraocular non-glaucomatous abnormality
History of ocular trauma or intraocular surgery other than uncomplicated glaucoma interventions or cataract extraction at least 3 months previous to participating in the study.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
5,000 Participants
are grouped into 4 trial groupsSponsors and collaborators
Wills Eye
Lead sponsor
National Eye Institute (NEI)
Collaborator
Source ClinicalTrials.gov